Synthesis and in Silico Docking Studies of Ethyl 2-(2-Arylidene-1-alkylhydrazinyl)thiazole-4-carboxylates as Antiglycating Agents.
Chem Biodivers
; 19(2): e202100581, 2022 Feb.
Article
em En
| MEDLINE
| ID: mdl-34875137
ABSTRACT
Ethyl 2-(2-arylidene-1-alkylhydrazinyl)thiazole-4-carboxylates (1a-k) were synthesized by alkylation on HN- of ethyl 2-(2-arylidenehydrazinyl)thiazole-4-carboxylates. The proposed structures (1a-k) are corroborated by spectro-analytical techniques like UV, FT-IR, 1 H-, 13 C-NMR and HR-MS. All synthesized compounds were screened for their antiglycation and antioxidant assays. The inâ
vitro antiglycation results revealed promising activity of compounds 1a, 1b, 1d, 1e, 1f, 1g, 1j and 1k with IC50 values 0.0004±1.097-17.22±0.538â
µM when compared to standard, aminoguanidine (IC50 =25.50±0.337â
µM). Among all tested compounds 1j and 1k are the best antiglycating agents with IC50 values 1.848±0.646 and 0.0004±1.097â
µM, respectively. The in-silico studies also agree with these results where binding energy for 1j and 1k was found to be -9.25 and -8.42â
kcal/mol with calculated dissociation constants of 0.16 and 0.67â
µM, respectively. The antiglycation results demonstrate the application of these compounds in reducing diabetic complications.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Tiazóis
/
Antineoplásicos
Idioma:
En
Revista:
Chem Biodivers
Assunto da revista:
BIOQUIMICA
/
QUIMICA
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Paquistão